Published in J Exp Med on September 08, 2009
The immune system in atherosclerosis. Nat Immunol (2011) 6.51
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation (2010) 2.69
Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol (2011) 2.27
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol (2009) 1.89
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol (2012) 1.71
Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. J Exp Med (2015) 1.58
Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest (2012) 1.57
Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol (2011) 1.57
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T cell homeostasis in mice. J Clin Invest (2011) 1.39
IL-17A is proatherogenic in high-fat diet-induced and Chlamydia pneumoniae infection-accelerated atherosclerosis in mice. J Immunol (2010) 1.36
SOCS, Inflammation, and Autoimmunity. Front Immunol (2012) 1.32
Treatment of allergic asthma: modulation of Th2 cells and their responses. Respir Res (2011) 1.31
Th17 response and inflammatory autoimmune diseases. Int J Inflam (2011) 1.29
Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest (2012) 1.27
The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment. Circ Res (2012) 1.24
The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells. Immunity (2012) 1.20
Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep (2012) 1.14
The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol (2013) 1.13
The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors (2012) 1.13
Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci (Landmark Ed) (2010) 1.11
The expression and functions of toll-like receptors in atherosclerosis. Mediators Inflamm (2010) 1.07
Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am (2010) 1.06
T cells in atherosclerosis. Int Immunol (2013) 1.03
Current views on the functions of interleukin-17A-producing cells in atherosclerosis. Thromb Haemost (2011) 1.03
Regulation of CD4+ T-cell polarization by suppressor of cytokine signalling proteins. Immunology (2012) 1.01
SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses. J Exp Med (2011) 1.01
The transcription factor CREB enhances interleukin-17A production and inflammation in a mouse model of atherosclerosis. Sci Signal (2013) 1.01
Cytokines in atherosclerosis: Key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev (2015) 1.00
Emerging role of IL-17 in atherosclerosis. J Innate Immun (2010) 0.99
Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis. J Biol Chem (2010) 0.99
The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol (2015) 0.98
Interleukin 17 in vascular inflammation. Cytokine Growth Factor Rev (2010) 0.98
CXCL5 limits macrophage foam cell formation in atherosclerosis. J Clin Invest (2013) 0.97
Infection and Atherosclerosis Development. Arch Med Res (2015) 0.96
B cell subsets in atherosclerosis. Front Immunol (2012) 0.95
Attenuated atherosclerotic lesions in apoE-Fcγ-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol (2011) 0.94
Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1. Immunology (2011) 0.92
Abrogated transforming growth factor beta receptor II (TGFβRII) signalling in dendritic cells promotes immune reactivity of T cells resulting in enhanced atherosclerosis. Eur Heart J (2012) 0.91
Mycophenolate mofetil decreases atherosclerotic lesion size by depression of aortic T-lymphocyte and interleukin-17-mediated macrophage accumulation. J Am Coll Cardiol (2011) 0.91
Phosphorylated STAT3 and PD-1 regulate IL-17 production and IL-23 receptor expression in Mycobacterium tuberculosis infection. Eur J Immunol (2014) 0.90
IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol (2014) 0.90
Elevated frequencies of circulating Th22 cell in addition to Th17 cell and Th17/Th1 cell in patients with acute coronary syndrome. PLoS One (2013) 0.89
Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17. Cytokine (2013) 0.88
Increased Th17 cell frequency concomitant with decreased Foxp3+ Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. Inflamm Res (2012) 0.87
The role of the vascular dendritic cell network in atherosclerosis. Am J Physiol Cell Physiol (2013) 0.87
Low-Dose IL-17 Therapy Prevents and Reverses Diabetic Nephropathy, Metabolic Syndrome, and Associated Organ Fibrosis. J Am Soc Nephrol (2015) 0.87
Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Ann Hematol (2010) 0.87
Plasmacytoid dendritic cells in atherosclerosis. Front Physiol (2012) 0.86
Fenofibrate inhibited the differentiation of T helper 17 cells in vitro. PPAR Res (2012) 0.86
Attenuation of experimental atherosclerosis by interleukin-19. Arterioscler Thromb Vasc Biol (2013) 0.86
Interleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution. Pulm Circ (2014) 0.85
Protective role of interleukin-17 in murine NKT cell-driven acute experimental hepatitis. Am J Pathol (2010) 0.85
Regulatory T cells and Atherosclerosis. J Clin Exp Cardiolog (2012) 0.85
The problem of accelerated atherosclerosis in systemic lupus erythematosus: insights into a complex co-morbidity. Thromb Haemost (2011) 0.85
T cells in vascular inflammatory diseases. Front Immunol (2014) 0.85
Lymphocyte migration into atherosclerotic plaque. Arterioscler Thromb Vasc Biol (2014) 0.85
Epinephrine-primed murine bone marrow-derived dendritic cells facilitate production of IL-17A and IL-4 but not IFN-γ by CD4+ T cells. Brain Behav Immun (2010) 0.84
Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res (2015) 0.83
Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol (2013) 0.83
IL-17 induces expression of vascular cell adhesion molecule through signalling pathway of NF-κB, but not Akt1 and TAK1 in vascular smooth muscle cells. Scand J Immunol (2013) 0.82
T helper cell polarization in healthy people: implications for cardiovascular disease. J Cardiovasc Transl Res (2013) 0.82
Clara cell 10-kDa protein inhibits T(H)17 responses through modulating dendritic cells in the setting of allergic rhinitis. J Allergy Clin Immunol (2012) 0.81
Interleukin-17 (IL-17) expression is reduced during acute myocardial infarction: role on chemokine receptor expression in monocytes and their in vitro chemotaxis towards chemokines. Toxins (Basel) (2012) 0.80
Stat3β mitigates development of atherosclerosis in apolipoprotein E-deficient mice. J Mol Med (Berl) (2013) 0.80
T lymphocyte autoreactivity in inflammatory mechanisms regulating atherosclerosis. ScientificWorldJournal (2012) 0.80
Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics. J Biomed Biotechnol (2010) 0.80
MicroRNAs and other mechanisms regulate interleukin-17 cytokines and receptors. Front Biosci (Elite Ed) (2012) 0.79
Egr2 and Egr3 are the unique regulators for systemic autoimmunity. JAKSTAT (2013) 0.79
Human monocyte-derived dendritic cells turn into foamy dendritic cells with IL-17A. J Lipid Res (2015) 0.78
The Th17/Treg imbalance in patients with cardiogenic shock. Clin Res Cardiol (2013) 0.78
Interleukin-22 Might Act as a Double-Edged Sword in Type 2 Diabetes and Coronary Artery Disease. Mediators Inflamm (2016) 0.78
Increased atherosclerotic lesion formation and vascular leukocyte accumulation in renal impairment are mediated by interleukin-17A. Circ Res (2013) 0.78
Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-/- mice. Ann Rheum Dis (2014) 0.78
Antiatherosclerotic potential of clopidogrel: antioxidant and anti-inflammatory approaches. Biomed Res Int (2013) 0.78
Interleukin-17 and acute coronary syndrome. J Zhejiang Univ Sci B (2013) 0.78
The Role of Immunogenicity in Cardiovascular Disease. World Heart J (2011) 0.77
Role of suppressor of cytokine signaling-1 in murine atherosclerosis. PLoS One (2012) 0.77
Reduced Atherosclerosis in apoE-inhibitory FcγRIIb-Deficient Mice Is Associated With Increased Anti-Inflammatory Responses by T Cells and Macrophages. Arterioscler Thromb Vasc Biol (2015) 0.77
B2 cells suppress experimental abdominal aortic aneurysms. Am J Pathol (2014) 0.76
Autophagic marker MAP1LC3B expression levels are associated with carotid atherosclerosis symptomatology. PLoS One (2014) 0.76
Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumtol (2012) 0.76
Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjögren's syndrome. Clin Exp Immunol (2014) 0.75
Aortic VCAM-1: an early marker of vascular inflammation in collagen-induced arthritis. J Cell Mol Med (2016) 0.75
Smooth Muscle Cell-Derived Interleukin-17C Plays an Atherogenic Role via the Recruitment of Proinflammatory Interleukin-17A+ T Cells to the Aorta. Arterioscler Thromb Vasc Biol (2016) 0.75
The immunology of atherosclerosis. Nat Rev Nephrol (2017) 0.75
Inhibition of RORα/γ suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation. Mol Metab (2016) 0.75
Opportunities for Translation from the Bench: Therapeutic Intervention of the JAK/STAT Pathway in Neuroinflammatory Diseases. Crit Rev Immunol (2015) 0.75
Interleukin 17A in Patients With Stable Coronary Artery Disease: Are There Differences According to Gender? Cardiol Res (2014) 0.75
Rebamipide ameliorates atherosclerosis by controlling lipid metabolism and inflammation. PLoS One (2017) 0.75
SOCS3: A novel therapeutic target for cardioprotection. JAKSTAT (2012) 0.75
The Roles of CD137 Signaling in Atherosclerosis. Korean Circ J (2016) 0.75
CXCR6 regulates the recruitment of pro-inflammatory IL-17A-producing T cells into atherosclerotic aortas. Int Immunol (2015) 0.75
Role of suppressors of cytokine signaling 3 in bone inflammatory responses. Front Immunol (2014) 0.75
TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy. J Immunol (2017) 0.75
T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol (2007) 12.20
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol (2008) 8.95
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 8.17
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature (2007) 7.07
SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol (2007) 6.89
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med (2003) 5.96
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A (2006) 5.69
Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev (2006) 5.27
Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med (2008) 4.76
Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med (2006) 4.38
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol (2003) 4.25
Innate and acquired immunity in atherogenesis. Nat Med (2002) 4.22
The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol (2008) 4.20
In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med (2008) 3.85
Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation (2009) 2.77
Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 2.21
SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med (2003) 2.20
Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation (2007) 2.00
Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol (2006) 1.99
Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol (2008) 1.98
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med (2006) 1.84
Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation (2002) 1.80
IL-17 produced by Paneth cells drives TNF-induced shock. J Exp Med (2008) 1.71
Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol (2007) 1.61
Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation (2003) 1.59
The Mollring Cutter remote endarterectomy: preliminary experience with a new endovascular technique for treatment of occlusive superficial femoral artery disease. J Endovasc Surg (1995) 1.59
Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem (2007) 1.37
Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.25
Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. Eur J Epidemiol (2004) 1.23
Coronary artery aneurysms in patients with hyper IgE recurrent infection syndrome. Clin Immunol (2006) 1.14
Anti-IL-17A autovaccination prevents clinical and histological manifestations of experimental autoimmune encephalomyelitis. Ann N Y Acad Sci (2007) 1.11
Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens. J Vasc Surg (2007) 1.08
The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. Am J Pathol (2005) 0.99
Critical aneurysmal dilatation of the thoracic aorta in young adolescents with variant hyperimmunoglobulin E syndrome. J Intern Med (2006) 0.84
Age and gender effects on apoptosis in the human coronary arterial wall. Mech Ageing Dev (2005) 0.83
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89
Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol (2008) 6.76
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A (2006) 5.69
Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature (2006) 5.49
Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation (2004) 5.28
Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev (2006) 5.27
Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity (2009) 5.10
Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest (2009) 4.74
The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell (2002) 4.72
Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell (2010) 4.57
Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med (2006) 4.28
IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol (2003) 4.25
Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nat Med (2006) 4.18
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity (2003) 4.07
Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res (2010) 4.06
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation (2008) 3.69
Suppressors of cytokine signaling and immunity. Nat Immunol (2003) 3.68
Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med (2004) 3.63
Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55
Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med (2009) 3.32
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A (2009) 3.31
SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity (2002) 3.25
Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J Immunol (2003) 3.07
Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem (2008) 2.97
Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev (2004) 2.94
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol (2009) 2.94
Single-molecule imaging analysis of Ras activation in living cells. Proc Natl Acad Sci U S A (2004) 2.84
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol (2004) 2.81
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA (2009) 2.72
Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol (2003) 2.71
The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol (2012) 2.69
In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation (2005) 2.69
Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev (2002) 2.69
Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res (2007) 2.69
An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol (2011) 2.69
Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet (2007) 2.55
CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol (2013) 2.38
Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity (2003) 2.33
Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology (2006) 2.33
TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J Clin Invest (2010) 2.32
Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med (2002) 2.23
Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 2.21
SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med (2003) 2.20
Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol (2005) 2.20
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
Lactadherin promotes VEGF-dependent neovascularization. Nat Med (2005) 2.19
Target cell defense prevents the development of diabetes after viral infection. Nat Immunol (2002) 2.18
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy. Circulation (2014) 2.16
Characterizing vulnerable plaque features with intravascular elastography. Circulation (2003) 2.07
Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res (2013) 2.05
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging (2011) 2.00
Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice. Circulation (2007) 2.00
Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol (2006) 1.99
Circulating microparticles: a potential prognostic marker for atherosclerotic vascular disease. Hypertension (2006) 1.99
Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.98
TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res (2008) 1.98
Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol (2008) 1.98
Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res (2008) 1.97
Endothelial microparticles in diseases. Cell Tissue Res (2008) 1.96
Enhanced leptin sensitivity and improved glucose homeostasis in mice lacking suppressor of cytokine signaling-3 in POMC-expressing cells. Cell Metab (2006) 1.96
Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res (2013) 1.96
Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation (2009) 1.94
Defective mer receptor tyrosine kinase signaling in bone marrow cells promotes apoptotic cell accumulation and accelerates atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 1.94
Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med (2012) 1.90
Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL-10 on lipopolysaccharide-induced macrophage activation. J Immunol (2002) 1.89
BAFF receptor deficiency reduces the development of atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol (2012) 1.87